Incyte Shares Jump After EMA Recommends Opzelura Approval; UBS Lifts Target
Incyte Corporation stock rallied intraday after the European Medicines Agency's committee issued a positive opinion for Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults. Analyst activity, an anticipated one-time CMS settlement benefit, and the company's planned acquisition of Vega Therapeutics added to the momentum, sending sha…